Ownership history in Redmile Group, LLC Β· 24 quarters on record
This page tracks every 13F SEC filing in which Redmile Group, LLC reported a position in BEAM THERAPEUTICS INC (BEAM). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Redmile Group, LLC outperformed the S&P 500 by +20.0% annually on this BEAM position. Timing score: 48% (11/23 decisions correct). Average cost basis: $26.24. Maximum drawdown during holding period: β86.8%.
π₯ Exceptional β beat the S&P 500 by 20.0% per year on this position.
23 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
11 of 23 add/trim decisions correct
Best entry: $18.00 (2020 Q1) Β· Worst: $81.64 (2020 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
5 adds Β· 19 trims. Bought during 2 of 12 down-price quarters. π Predominantly trimming β distribution phase.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 2.62% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size